News und Analysen
THERANEXUS : DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS
Lyon, August 6, 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
Antibe Therapeutics Engages Stern IR for Investor Relations Services
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. (“Stern IR”) to expand the Company’s investor relations program and support
True Leaf informiert über aktuellen Stand des Umstrukturierungsprozesses
Vernon (British Columbia), 5. August 2020. True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FWB: TLA) („True Leaf“) gibt heute bekannt, dass True Leaf und seine Tochtergesellschaften am 31.
True Leaf Provides Update on Restructuring Process
Vernon, BC - August 5, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FSE: TLA) (“True Leaf”) announced today that, on July 31, 2020, True Leaf and its subsidiaries obtained Orders
Antibe Therapeutics Provides Corporate Update
Antibe Therapeutics Inc.:
- Phase II secondary data confirmed remarkable potency of ATB-346 -
- 3rd party commercial studies project peak annual sales of $5.3 billion across seven key countries
Neutrisci Receives Final Approval from The Japanese Health Ministry
Vancouver, British Columbia – August 4, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company
NeutriSci erhält vom japanischen Gesundheitsministerium die finale Produktzulassung
Vancouver, British Columbia – 4. August 2020 – NeutriSci International Inc. („NeutriSci“ oder das „Unternehmen“) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), ein innovatives
THERANEXUS TO PRESENT THE RESULTS OF THN102 FOR PARKINSON'S DISEASE AT THE 2020 INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS
The MDS Virtual Congress will take place from 12 to 16 September 2020.
Lyon, 30 July 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer
Sensorion appoints five renowned experts to its Scientific Advisory Board
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
VALBIOTIS meldet einen Kassenstand von 10,9 Millionen Euro zum 30. Juni 2020
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Prävention und Bekämpfung von
VALBIOTIS Announces a Cash Position of €10.9M at 30 June 2020
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic
Antibe Therapeutics Reports 2020 Year-End Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020
Lysogene: First Half 2020 Business Update
Lysogene (Paris:LYS)(FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, provides H1 2020 Business update.
As of 30 June 2020, cash and
True Leaf Provides Update on Filing of Year End 2020 and First Quarter 2021 Financial Statements
Vernon, BC - July 21, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FSE: TLA) (“True Leaf” or the “Company”) is providing an update on the status of the filing of its operating and
True Leaf meldet Update zur Einreichung des Jahresabschlusses für 2020 und des Zwischenabschlusses für das erste Quartal 2021
Vernon (British Columbia), 21. Juli 2020. True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FWB: TLA) („True Leaf“) informiert über den aktuellen Stand der Einreichung seiner Betriebs- und
Heat Biologics: Erste NBC-Empfehlung mit +1.375% in 5 Monaten
Mit Heat Biologics (WKN: A2JB4Y) kannte die erste Empfehlung des weltweit einzigartig erfolgreichen No Brainer Clubs zuletzt kein Halten mehr. Seit Ende Februar steht eine Kursperformance von
Sensorion Will Present at the Bioprocessing Summit Europe Virtual Conference on July 21-23, 2020
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
VALBIOTIS gewährt dem neuen Aktionär AMIRAL GESTION Kapitalzugang zu einem Preis von 4,50 € pro Aktie, entsprechend einer Prämie von 5,4% im Vergleich zum Börsenschlusskurs vom 16. Juli 2020
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL, für den französischen PEA/KMU qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur
VALBIOTIS meldet erste Visite des ersten Patienten in der internationalen, klinischen Phase-II/III-Studie REVERSE-IT zu TOTUM-63 zur Reduktion von Risikofaktoren für Typ-2-Diabetes
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Sensorion Hosting Key Opinion Leader Call with Dr. Michael Hoffer on Sudden Sensorineural Hearing Loss and SENS-401 as a Potential Treatment Option on July 23, 2020
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering, clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
VALBIOTIS Announces the First Patient First Visit in the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63 to Reduce Type 2 Diabetes Risk Factors
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME eligible) a Research & Development company committed to scientific innovation for preventing and combating metabolic
THERANEXUS ANNOUNCES ITS CASH POSITION AS OF 30 JUNE 2020 AND IMPLEMENTATION OF A MANDATORY CONVERTIBLE BOND FACILITY
- Pro forma cash of €13.3 M at 30 June 2020
- Implementation of financing for a maximum total of €4.2 million over 12 months through the issuance of warrants to subscribe mandatory convertible bonds
VALBIOTIS: Start der internationalen klinischen Studie Phase-II/III-REVERSE-IT zu TOTUM-63 zur Verringerung der Risikofaktoren für Typ-2-Diabetes genehmigt
VALBIOTIS (FR0013254851 - ALVAL / PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
VALBIOTIS: Authorization to Launch the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63, to Reduce Type 2 Diabetes Risk Factors
Regulatory News:
VALBIOTIS (FR0013254851 - ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation, for preventing and combating metabolic diseases
Sensorion Appoints Dr Edwin Moses, Former Ablynx CEO, as Chairman of the Board
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering, clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and